Saturday, January 24, 2026

 IT'S A QUANTUM UNIVERSE

Researchers publish new guide to measuring spacetime fluctuations



Signatures of Correlation of Spacetime Fluctuations in Laser Interferometers




University of Warwick

Image of tabletop QUEST setup for measuring spacetime fluctuations 

image: 

Cardiff's Gravity Exploration Institute team working on QUEST experiment. Credit: H Grote, Cardiff University.

view more 

Credit: H Grote, Cardiff University




A team of researchers led by the University of Warwick has developed the first unified framework for detecting “spacetime fluctuations” - tiny, random distortions in the fabric of spacetime that appear in many attempts to unite quantum physics and gravity.

These subtle fluctuations, first envisaged by physicist John Wheeler, are thought to arise naturally in several leading theories of quantum gravity. But because different models of gravity predict different forms of these fluctuations, experimental teams have until now lacked clear guidance on what to look for.

The new study, published in Nature Communications addresses this challenge by sorting spacetime fluctuations into three broad categories, each defined by how organised the fluctuations are in space and time. For each category, the researchers mapped out the distinct, measurable signatures that would appear in laser interferometers - from the 4km long LIGO, to compact laboratory systems such as QUEST and GQuEST being developed in the UK (Cardiff University) and USA (Caltech) respectively.

Dr. Sharmila Balamurugan, Assistant Professor, University of Warwick and first author said: “Different models of gravity predict very different underlying trends in the random spacetime fluctuations, and that has left experimentalists without a clear target. Our work provides the first unified guide that translates these abstract, theoretical predictions into concrete, measurable signals.

“It means we can now test a whole class of quantum-gravity predictions using existing interferometers, rather than waiting for entirely new technologies. This is an important step towards bringing some of the most fundamental questions in physics firmly into the realm of experiment.”

The study found that:

  • Tabletop interferometers beat LIGO in bandwidth
     Despite being far smaller than LIGO, QUEST and GQuEST could provide more detailed information about the nature of spacetime fluctuations. Their wide frequency coverage allows them to detect all the characteristic signatures.
  • LIGO is an excellent “yes/no” detector.
     Thanks to its long arm cavities, LIGO is highly sensitive to the mere presence of spacetime fluctuations — although the relevant frequencies lie above the range currently available in public data.
  • A long-running debate is resolved.
     A debate about whether arm cavities help or hinder detection has been answered as here arm cavities do enhance an interferometer’s sensitivity to spacetime fluctuations, depending on the type of fluctuation being tested.

Dr. Sander Vermeulen, Caltech, co-author of the study said: “Interferometers can measure spacetime with extraordinary precision. However, to measure spacetime fluctuations with an interferometer, we need to know where - i.e. at what frequency - to look, and what the signal will look like. With our framework we can now predict this for a wide range of theories. Our results show that interferometers are powerful and versatile tools in the quest for quantum gravity.”

Crucially, the new framework developed here is agnostic of the underlying mechanism for the fluctuations: it requires only the mathematical description of the hypothesised fluctuations and the geometry of the instrument. This makes it a powerful tool not only for quantum-gravity tests but also for searches for stochastic gravitational waves, dark-matter signatures, and certain forms of instrumental noise.

Prof Animesh Datta, Professor of Theoretical Physics at Warwick concluded: “With this methodology, we can now treat any proposed model of spacetime fluctuations in a consistent, comparable way. In the coming years, we can use this to design smarter tabletop interferometers to confirm or refute possible theories of quantum or semiclassical gravity and even test new ideas about dark matter and stochastic gravitational waves.”

ENDS

Notes to Editors

Image Credits: H Grote, Cardiff University.

About the paper and funding:

The paper ‘Signatures of Correlation of Spacetime Fluctuations in Laser Interferometers’ has been published in Nature Communications. DOI: https://doi.org/10.1038/s41467-025-67313-3

This work was funded by the UK STFC “Quantum Technologies for Fundamental Physics” program (Grant Numbers ST/T006404/1, ST/W006308/1 and ST/Y004493/1) and the Leverhulme Trust under research grant ECF-2024-124 and RPG-2019-022.

 About the University of Warwick

Founded in 1965, the University of Warwick is a world-leading institution known for its commitment to era-defining innovation across research and education. A connected ecosystem of staff, students and alumni, the University fosters transformative learning, interdisciplinary collaboration, and bold industry partnerships across state-of-the-art facilities in the UK and global satellite hubs. Here, spirited thinkers push boundaries, experiment, and challenge conventions to create a better world.

XXI CENTURY ALCHEMY

'Trojan horse' may deliver toxic dose of copper to bacterial colonies, including drug-resistant MRSA infections




University of Arizona




A research team at the University of Arizona College of Medicine – Tucson is developing a drug that works in combination with copper to kill bacteria, including those that cause MRSA, a type of staph infection that is resistant to usual treatments. They published their results last month in mSphere.

MRSA is caused by methicillin-resistant Staphylococcus aureus, which is classified as a serious threat by the Centers for Disease Control and Prevention and a high-priority pathogen by the World Health Organization.

"It likes to live on our skin – about 30% of people are colonized with it. It becomes a problem when it gets in a wound, where it can wreak havoc," said Michael D. L. Johnson, an associate professor of immunobiology and senior author of the paper.

While MRSA can be treated with other antibiotics, bacteria's ability to evolve drug resistance means finding novel treatments is crucial.

"History has shown us that bacteria have an exquisite ability to adapt to their surroundings," Johnson said. "The more tools we have in our toolkit, the better prepared we will be to fight the next threat."

MRSA can be spread by skin-to-skin contact and appear as a painful boil. It can also occur in a hospital setting, where it might colonize a surgical wound or be introduced to the body through tubing, such as a catheter, or an implant, such as an artificial joint.

"People who are diabetic are very susceptible to staph infections, specifically in wounds they may develop," Johnson said. "It also binds to plastic really well. Can you guess where there's a lot of plastic? In a hospital. We've become quite reliant on plastic, which creates a niche for that microbe."

The team also looked at a cousin of MSRA, Staphylococcus epidermidis, which is usually harmless but can cause infections in hospitals due to its affinity for plastic. Both MSRA and S. epidermidis adhere to plastic by producing a "glue" called biofilm.

"That stuff you feel on your teeth when you wake up in the morning – that's biofilm," Johnson said. "Bacteria make biofilm to hold on to host cells or surfaces, and that biofilm is a protective shield from the bacteria's environment – such as antibiotics or antimicrobial peptides our bodies make."

Supported by funding from Tech Launch Arizona, the Johnson Lab designed the platform for a molecule called BMDC, short for N-benzyl-N-methyldithiocarbamate, to work with copper, based on a similar molecule they studied previously. TLA provided the funds through its Asset Development Program, which provides support to move potentially impactful innovations closer to readiness for commercialization and real-world impact.

"This one actually worked better than our original compound, DMDC, which killed different Streptococcusspecies – but not staph," Johnson said.

He says BMDC works by disguising itself as iron, a nutrient that hungry bacteria scavenge from their surroundings. But instead of iron, the compound contains a toxic dose of copper.

"Our compound mimics specialized molecules that carry iron. The staph bacteria are like, 'Oh, sweet, iron! This is my lucky day!' They unlock the compound, and, oops, it's copper," he explained. "Our compound is a Trojan horse, intoxicating bacteria with copper, killing them within the biofilm. The bacteria don't learn from their mistakes, and they do it over and over again."

Working with TLA, Johnson has filed a patent application on the technology, and they are searching for a company to license the product to develop it further. Their plan is to take it to clinical trials in humans, which they hope will lead to FDA approval to treat MRSA and other infections.

In the meantime, the Johnson Lab is preparing to launch a collaboration with the Department of Surgery's Division Chief of Pediatric Surgery Kenneth W. Liechty, to conduct additional laboratory experiments to see if their compound helps with wound infections and healing.

"How amazing would it be if someday, we could put some of our stuff on an open wound with a bad infection, and the infection got better?" said Johnson, who is also a member of the BIO5 Institute. "We're very interested in the translation of our discoveries to the clinic, and you don't do that unless you're partnered with amazing people here at U of A to do those experiments."

Johnson says the possibility that his work in the lab could someday benefit humanity is profoundly inspiring.

"Those are the things basic science and translational researchers dream about," he said. "It makes the science more exciting when you can see the application at the end of the road."

This research is supported in part by the National Institute of General Medical Sciences, a division of the National Institutes of Health, under award No. 2R35128653.

ABOLISH PBM MIDDLE MEN 

PBM profits obscured by mergers and accounting practices, USC Schaeffer white paper shows



Requiring more financial transparency from PBMs would help policymakers understand how money flows through the large healthcare companies that now own them




University of Southern California




Pharmacy benefit managers (PBMs) under the microscope for their role in high drug prices have often cited their reportedly slim profit margins as evidence that they do not drive up costs. The three leading PBMs, which control about 80% of the prescription drug market, have historically reported profit margins of 4% to 7%, among the lowest in the healthcare industry.

A new white paper from the USC Schaeffer Center for Health Policy & Economics demonstrates that these slim margins are dramatically influenced by the accounting practices PBMs elect to employ. The paper also shows how efforts to assess PBM profits have become more challenging after these companies merged with healthcare conglomerates that own other players in the pharmaceutical supply chain.

States in recent years have advanced or considered numerous measures seeking to increase PBM transparency, and Congress is currently pursuing legislation to reform PBM practices. The Federal Trade Commission, meanwhile, continues to scrutinize PBMs after accusing leading firms of inflating drug costs through strategies like rebates, markups and preferential treatment of affiliated pharmacies.

“Accounting practices make it difficult to judge the health and efficiency of the PBM market, particularly as dominant firms have become part of larger, more complex companies,” said lead author Karen Mulligan, a research scientist at the Schaeffer Center. “Greater financial disclosure requirements for PBMs are needed to develop a better picture of how PBMs make money and the extent to which these practices may raise costs for consumers.”

How accounting choices drive margins

PBMs sit at the center of the pharmaceutical supply chain, acting as intermediaries that pay pharmacies and negotiate rebates with drug manufacturers on behalf of insurers. PBMs retain transaction fees and a portion of manufacturer rebates while passing along payments between manufacturers, insurers and pharmacies.

Historically, PBMs have included these “pass-through payments” in financial reporting. This may also include the share of rebates sent directly to the insurer. While allowed under professional accounting guidelines, this practice may add hundreds of billions of dollars to PBMs’ reported revenue or expenses without affecting their actual earnings. This obscures key determinants of PBMs’ profitability, including the role of rebates, fees and other payments.

Using a simplified example with typical transaction fees and rebates, the white paper illustrates how accounting choices can produce vastly different profit margins for a hypothetical drug listed at $360. If pass-through payments were reported as revenues or expenses, the PBM’s margin would be 10% – or slightly higher at 13% if manufacturer rebates passed to the insurer were not reported. However, the margin jumps to 87% if pass-through payments were not reported at all. (See Figure 5 in the white paper.)

Vertical integration in the healthcare industry has further blurred PBMs’ financial picture. In the past decade, the three dominant PBMs have become part of diverse healthcare corporations that also own insurers, specialty pharmacies and group purchasing organizations (GOPs) that negotiate discounts.

Under this structure, payments between the PBM, insurer and the specialty pharmacy become internal transfers invisible to the public. Using the same hypothetical $360 drug as the previous example, the white paper shows how the publicly reported profit margin can be half of what’s recorded internally, as dollars are shifted to other units within the PBM’s parent company. (See Figure 6.)

Transparency reforms should illuminate revenue streams

The researchers suggest that policymakers consider requiring PBMs to exclude pass-through payments from financial reporting, as regulators have done for intermediaries in other industries.

Policymakers should also consider reforming financial reporting requirements so that healthcare conglomerates provide separate reporting for each distinct business unit, rather than allowing PBM operations to be combined with other units like specialty pharmacy. Further, requiring disclosure of internal transfers and pass-through payments in these companies would provide clarity about what’s driving profits.

“True transparency requires greater visibility into profit flows hidden inside increasingly complex corporate structures,” said co-author Darius Lakdawalla, chief scientific officer at the Schaeffer Center and the Quintiles Chair of Pharmaceutical Development and Regulatory Innovation at the USC Mann School. “Building a more efficient and sustainable pharmaceutical supply chain starts with a better understanding of where dollars are flowing.”